Targeted ATMP CDMO Recipharm Advanced Bio specializes in pre-clinical to clinical development and manufacturing for advanced therapy medicinal products, presenting a clear sales angle to biotechs and gene therapy startups seeking a capable partner from early development through commercial production.

Viral and Nucleic Acid Focus With capabilities spanning live viruses, viral vectors, live-biotherapeutic products, mRNA, and plasmid DNA, there is a strong cross-sell opportunity to customers pursuing viral immunotherapies, gene therapies, or nucleic acid–based platforms needing integrated development and GMP manufacturing.

Strategic Collaboration Recent collaboration with Fusix Biotech signals openness to joint development and manufacturing ventures, suggesting a receptive posture for co-development deals, technology transfer arrangements, and long-term supply partnerships for next-generation cancer therapies.

Global Health Scale As a global CDMO under the Recipharm umbrella with a revenue range of 100–250 million and a specialized ATMP focus, the company can be positioned as a scalable partner capable of supporting clinical trials through to commercial launch for mid-sized to large biotech clients.

Strategic Fit with Biotechs Smaller yet specialized team size (51–200 employees) paired with deep technical expertise provides a compelling option for mid-stage companies seeking dedicated, focused CDMO attention, faster decision cycles, and flexible engagement models to accelerate time-to-market.